Secondary hyperparathyroidism and target organs in chronic kidney disease

Hippokratia

Volumn 15, Issue SUPPL. 1, 2011, Pages 33-38

  Nikodimopoulou, M ^a   Liakos, S ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Cardiovascular disease; iPTH; Vitamin D

Indexed keywords

CALCITRIOL; CALCIUM; PARATHYROID HORMONE; PHOSPHORUS; VITAMIN D; VITAMIN D RECEPTOR;

ANEMIA; BONE MINERALIZATION; CALCIFICATION; CALCIUM METABOLISM; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DISEASE COURSE; FRAGILITY FRACTURE; HEART DISEASE; HEART HYPERTROPHY; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; IMMUNOPATHOLOGY; KIDNEY FAILURE; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; NONHUMAN; OSTEOSCLEROSIS; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROID HYPERPLASIA; PATHOGENESIS; PHOSPHATE METABOLISM; PROTEIN EXPRESSION; RENAL OSTEODYSTROPHY; REVIEW; SECONDARY HYPERPARATHYROIDISM;

EID: 79952461055     PISSN: 11084189     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Hsu CY, Chertow GM. Chronic renal confusion: Insufficiency, failure, dysfunction, or disease. Am J Kidney Dis 2000; 36: 415-418.
2. Lindberg JS, Moe SM. Osteoporosis in end-stage renal disease. Semin Nephrol 1999; 19: 115-122.
3. Alem AM, Sherrard DJ, Gillen DL, Weiss NS, Beresford SA, Heckbert SR, et al. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 2000; 58: 396-399.
4. Frassetto LA, Morris RC Jr, Sebastian A. Effect of age on blood acid-base composition in adult humans: Role of age-related renal functional decline. Am J Physiol 1996; 271: F1114-F1122.
5. Lemann J, Litzow JR, Lennon EJ. The effects of chronic acid loads in normal man: Further evidence for the participation of bone mineral in the defense against chronic metabolic acidosis. J Clin Invest 1966; 45: 1608-1614.
6. Pitts TO, Piraino BH, Mitro R, Chen TC, Segre GV, Greenberg A, et al. Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure. J Clin Endocrinol Metab 1988; 67: 876-881.
7. Malluche HH, Ritz E, Lange HP, Kutschera L, Hodgson M, Seiffert U, et al. Bone histology in incipient and advanced renal failure. Kidney Int 1976; 9: 355-362.
8. Rix M, Andreassen H, Eskildsen P, Langdahl B, Olgaard K. Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure. Kidney Int 1999; 56: 1084-1093.
9. Cummings SR, Browner WS, Bauer D, Stone K, Ensrud K, Jamal S, et al. Endogenous hormones and the risk of hip and vertebral fractures among older women. N Engl J Med 1998; 339: 733-738.
10. Yendt ER, Cohanim M, Jarzylo S, Jones G, Rosenberg G. Reduced creatinine clearance in primary osteoporosis in women. J Bone Miner Res. 1993; 8: 1045-1052.
11. Jones CA, McQuillan GM, Kusek JW, Eberhardt MS, Herman WH, Coresh J, et al. Serum creatinine levels in the US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 1998; 32: 992-999.
12. Spaulding CM, Young G. Osteitis fibrosa cystica and chronic renal failure. J Am Pediatr Med Assoc 1997; 87: 238-240.
13. Jevtic V. Imaging of renal osteodystrophy. Eur J Radiol 2003; 46: 85-95.
14. Gavelli G, Zompatori M. Thoracic complications in uremic patients and in patients undergoing dialytic treatment: state of the art. Eur Radiol 1997; 7: 708-717.
15. Wittenberg A. The rugger jersey spine sign. Radiology 2004; 230: 491-492.
16. Fineman I, Johnson JP, Di-Patre PL, Sandhu H. Chronic renal failure causing brown tumors and myelopathy. Case report and review of pathophysiology and treatment. J Neurosurg 1999; 90 (2 Suppl): 242-246.
17. Leal CT, Lacativa PG, Gomes EM, Nunes RC, Costa FL, Gandelmann IH, et al. Surgical approach and clinical outcome of a deforming brown tumor at the maxilla in a patient with secondary hyperparathyroidism due to chronic renal failure. Arq Bras Endocrinol Metabol 2006; 50: 963-967.
18. Whyte MP. Extraskeletal (ectopic) calcification and ossification. In: Favus MJ, editor. Primer on the metabolic bone diseases and disorders of mineral metabolism. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 1999. p. 427-429.
19. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998;31(4): 607-617.
20. Baums MH, Klinger HM, Otte S. Morbus Teutschldnder - a massive soft-tissue calcification of the foot in a patient on long-term hemodialysis. Arch Orthop Trauma Surg 2003; 123: 51-53.
21. Dróeke TB. A clinical approach to the uraemic patient with extraskeletal calcifications. Nephrol Dial Transplant 1996; 11: 37-42.
22. Schwarz C, Sulzbacher I, Oberbauer R. Diagnosis of renal osteodystrophy. Eur J Clin Invest 2006; 36: 13-22.
23. Torres A, Lorenzo V, Hernandez D, et al. Bone disease in predialysis, hemodialysis, and CAPD patients: evidence of a better bone response to PTH. Kidney Int 1995; 47: 1434-1442.
24. Parfrey PS, Harnett JD, Barre PE. The natural history of myocardial disease in dialysis patients. J Am Soc Nephrol 1991; 2: 2-12.
25. Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995; 47: 186-192.
26. Foley RN, Parfrey PS. Cardiac disease in chronic uremia: clinical outcome and risk factors. Advances in Renal Replacement Therapy 1997; 4: 234-248.
27. Verma A, Anavekar NS, Meris A, Thune JJ, Arnold JM, Ghali JK, et al. The relationship between renal function and cardiac structure, function, and prognosis after myocardial infarction: the VALIANT Echo Study. J Am Coll Cardiol 2007; 50: 1238-1245.
28. Strózecki P, Adamowicz A, Nartowicz E, Odrowaz-Sypniewska G, Wlodarczyk Z, Manitius J, et al. Parathormone, calcium, phosphorus and left ventricular structure and function in normotensive hemodialysis patients. Renal Failure 2001; 23: 115-126.
29. Pocotte S, Ehrensten G, Fitzpatrick LA. Regulation of parathyroid hormone secretion. Endocr Rev 1991; 12: 291-301.
30. Schluter K-D, Piper HM. Cardiovascular actions of parathyroid hormone and parathyroid hormone-related peptide. Cardiovasc Res 1998; 37: 34-41.
31. Piovesan A, Molineri N, Casasso F, Emmolo I, Ugliengo G, Cesario F, et al. Left ventricular hypertrophy in primary hyperparathyroidism. Effects of successful parathyroidectomy. J Clin Endocrinol 1999; 50: 321-328.
32. London GM, De Vernejoul MC, Fabiani F, Marchais SJ, Guerin AP, Metivier F, et al. Secondary hyperparathyroidism and cardiac hypertrophy in hemodialysis patients. Kidney Int 1987; 32: 900-907.
33. Park CW, Oh YS, Shin YS, Kim CM, Kim YS, Kim SY, et al. Intravenous calcitriol regress myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 1999; 33: 73-81.
34. Barletta G, De Feo ML, Del Bene R, Lazzeri C, Vecchiarino S, La Villa G, et al. Cadiovascular effects of parathyroid hormone: A study in healthy subjects and normotensive patients with mild primary hyperparathyroidism. J Clin Endocrinol Metab 2000; 85: 1815-1821.
35. Stefenelli T, Abela C, Frank H, Koller-Strametz J, Globits S, Bergler-Klein J, et al. Cardiac abnormalities in patients with primary hyperparathyroidism: Implications for follow-up. J Clin Endocrinol Metab 1997; 82: 106-112.
36. Näppi S, Saha H, Virtanen V, Limnell V, Sand J, Salmi J, et al. Left ventricular structure and function in primary hyperparathyroidism before and after parathyroidectomy. Cardiology 2000; 4: 229-233.
37. Lips P, Duong T, Oleksik A. A global study of vitamin D and parathyroid function in postmenopausal women with osteoporosis: baseline data from the multiple outcomes of raloxifene evaluation clinical trial. J Clin Endocrinol Metab 2001; 86: 1212-1221.
38. Bodyak N, Ayus JC, Achinger S, Shivalingappa V, Ke Q, Chen YS, et al. Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci USA 2007; 104: 16810-16815.
39. De Fronzo RA, Tobin JD, Rowe JW, Andres R. Glucose intolerance in uremia. Quantification of pancreatic betacell sensitivity to glucose and tissue sensitivity to insulin. J Clin Invest 1978; 62: 425-435.
40. De Fronzo RA, Alverstrand A, Smith D, Hendler R, Hendler E, Wahren J. Insulin resistance in uremia. J Clin Invest 1981; 67: 563-568.
41. De Fronzo RA. Pathogenesis of glucose intolerance in uremia. Metab Clin Exp 1978; 27: 1866-1880.
42. Goldstein DA, Feinstein EI, Chui LA, Pattabhiraman R, Massry SG. The relationship between the abnormalities in electroencephalogram and blood levels of PTH in dialysis patients. J Clin Endocrinol Metab 1980; 51: 130-134.
43. Avram MD, Feinfeld DA, Huatuco AH. Search for the uremic toxin. Decreased motor nerve conduction velocity and elevated parathyroid hormone in uremia. N Engl J Med 1978; 298: 1000-1004.
44. Remuzzi G, Benigni A, Dodesini P, Schieppati A, Livio M, Poletti E, et al. Parathyroid hormone inhibits human platelet function. Lancet 1982; 11: 1321-1324.
45. Garber AJ. Effect of parathyroid hormone on skeletal muscle protein and amino acid metabolism in the rat. J Clin Invest 1983; 71: 806-821.
46. Peppa M, Uribarri J, Vlassara H. The role of advanced glycation end products in the development of atherosclerosis. Curr Diab Rep 2004; 4: 31-36.
47. Vlassara H, Bucala R, Striker L. Biology of disease: pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. J Lab Invest 1994; 70: 138-151.
48. Greten J, Kreis I, Weisel K, Stier E, Schmidt AM, Stern DM, et al. Receptors for advanced glycation end-products (AGE)- expression by endothelial cells in nondiabetic uraemic patients. Nephrol Dial Transplant 1996; 11: 786-790.
49. Seino Y, Ikeda U, Ikeda M, Yamamoto K, Misawa Y, Hasegawa T, et al. Interleukin 6 gene transcripts are expressed in human atherosclerotic lesions. Cytokine 1994; 6: 87-91.
50. Kalinowski L, Dobrucki LW, Malinski T. Nitric oxide as a second messenger in parathyroid hormone-related protein signaling. J Endocrinol 2001; 170: 433-440.
51. Throckmorton D, Kurscheid-Reich D, Rosales OR, Rodriguez-Commes J, Lopez R, Sumpio B, et al. Parathyroid hormone effects on signaling pathways in endothelial cells vary with peptide concentration. Peptides 2002; 23: 79-85.
52. Attman PO, Samuelsson O, Alupovic P. Lipoprotein metabolism and renal failure. Am J Kidney Dis 1993; 21: 573-593.
53. Massry SG, Smogorzewski M. Mechanisms through which parathyroid hormone mediates its deleterious effects on organ function in uremia. Sem Nephrol 1994; 14: 219-231.
54. Klin M, Smogorzewski M, Massry SG. Chronic renal failure increases cytosolic [Ca21]i of hepatocytes. Am J Physiol 1995; 269: G103-G109.
55. Massry SG, Klin M, Ni Z, Tian J, Kedes L, Smogorzewski M. Impaired agonist-induced calcium signaling in hepatocytes from chronic renal failure. Kidney Int 1995; 48: 1324-1331.
56. Tian J, Smogorzewski M, Kedes L, Massry SG. PTHPTHrP receptor is down-regulated in chronic renal failure. Am J Nephrol 1995; 14: 41-46.
57. Smogorzewski M, Tian J, Massry SG. Downregulation of PTHPTHrP receptor in heart in CRF: Role of [Ca21]i. Kidney Int 1995; 47: 1182-1186.
58. Brenza H, Kimmel-Jehan L, Jehan C, Shinki F, Wakino T, Anazawa S, et al. Proc Natl Acad Sci USA 1997; 95: 1387-1391.
59. DeLuca H, Zierold C. Mechanisms and functions of vitamin D. Nutr Rev 1998; 56: S4-S10.
60. Demay M, Kiernan M, DeLuca H, Kronenberg H. Sequences in the human parathyroid hormone gene that bind the 1,25-dihydroxyvitamin D3 receptor and mediate transcriptional repression in response to 1,25-dihydroxyvitamin D3. Proc Natl Acad Sci USA 1992; 89: 8097-8101.
61. Brown A, Zhong M, Finch J, Ritter C, Slatopolsky E. The roles of calcium and 1, 25-dihydroxyvitamin D3 in the regulation of vitamin D receptor expression by rat parathyroid glands. Endocrinology 1995; 136: 1419-1425.
62. Healy K, Zella J, Prahl J, DeLuca H. Regulation of the murine renal vitamin D receptor by 1,25-dihydroxyvitamin D3 and calcium. Proc Natl Acad Sci USA 2003; 100: 9733-9737.
63. van Leeuwen J, Birkenhager J, Vink-van Wijngaarden T, van den Bemd G, Pols H. Regulation of 1,25-dihydroxyvitamin D3 receptor gene expression by parathyroid hormone and cAMPagonists. Biochem Biophys Res Commun 1992; 185: 881-886.
64. Reinhardt T, Horst R. Parathyroid hormone down-regulates 1,25-dihydroxyvitamin D receptors (VDR) and VDR messenger ribonucleic acid in vitro and blocks homologous up-regulation of VDR in vivo. Endocrinology 1990; 127: 942-948.
65. Dardenne O, Prud'homme J, Arabian A, Glorieux FH, St-Arnaud R. Targeted inactivation of the 25-hydroxyvitamin D(3)-1(alpha)- hydroxylase gene (CYP27B1) creates an animal model of pseudovitamin D-deficiency rickets. Endocrinology 2001; 142: 3135-3141.